| Revenue growth | 56.21% YoY growth in FY26. |
|---|---|
| Margins | EBITDA margin at 16.7% in FY26 vs 20.7% in FY25. |
| Order book | Healthy order book mentioned by MD. |
| Demand visibility | Robust momentum in core export markets: Africa, SE Asia, Latin America. |
| Management confidence | High; confident in profitability improvement as investments yield results. |
Growth
Revenue grew 56.21% YoY to ₹89.6 cr; PAT increased 42.3% YoY to ₹9.67 cr.
Outlook
Focus on 100+ products under registration and scaling CDMO capacity to improve operating leverage.
Risks
Margins impacted by product mix changes, upfront registration costs, and compliance-related expenses.
Earnings Call filed with NSE, NSE: ACCPL. Summary written with AI assistance from the document.
Accretion Pharmaceuticals Ltd: key numbers
- Share price
- ₹203.30
- Market cap
- ₹226.0 Cr
- Revenue (annual)
- ₹89.63 Cr
- Net profit (annual)
- ₹9.67 Cr
- P/E (TTM)
- 23.4×Sector 50.4×
- Promoter holding
- 73.52%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accretion Pharmaceuticals Ltd
All →Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).
Accretion Pharmaceuticals H2 FY26 Results: Net Profit ₹4.9 Cr, Up 14.0% YoY
Accretion Pharmaceuticals Ltd reported revenue from operations of ₹45.9 Cr (+18.3% YoY) and net profit of ₹4.9 Cr (+14.0% YoY) for H2 FY26.
- Key figure
- Net profit ₹4.9 Cr · +14.0% YoY